Observational studyRevista medica del Instituto Mexicano del Seguro Social2025
[Clinical characterization in patients with neurocutaneous syndrome].
Observational study in Revista medica del Instituto Mexicano del Seguro Social, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neurocutaneous syndromes are a group of genetic diseases that affect the skin, eyes, central and peripheral nervous systems. They include Neurofibromatosis type 1 (NF1), Tuberous sclerosis (TS), Von-Hippel Lindau disease, Neurofibromatosis type 2 (NF2), Ataxia Telangiectasia (AT) and Hypomelanosis of Ito. Objective: To characterize the most frequent clinical manifestations in Neurocutaneous syndromes. Methods: A descriptive, observational, cross-sectional and ambivalent study was carried out in the Genetics service of the General Hospital of Zone No. 20. Patients diagnosed with any neurocutaneous syndrome of any age were included and agreed to participate in the study. Results: Thirty-nine patients were reviewed, 21 patients (53.8%) were women and 18 (46.2%) were men. The median age of the patients was 12 years, with an interquartile range (25th-75th percentiles) of 6 and 17 years, respectively. The most frequent neurocutaneous syndromes were NF1 (62%) and ET (18%). All patients presented cutaneous manifestations, and 16 patients (42.1%) presented at least one neurological manifestation. Conclusions: The timely interpretation of skin changes as primary lesions becomes a valuable instrument for the early identification of any neurological alteration; likewise, the search for skin changes should be carried out in all patients undergoing initial study for neurological manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.